We expect Biogen (BIIB) to beat expectations when it reports fourth-quarter and full-year 2023 results on Feb 13, before market open. In the last reported quarter, the company delivered an earnings surprise of 9.27%.Factors to ConsiderBiogen’s sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and rising competitive pressure in the MS market. Tecfidera sales have been declining as multiple generic versions of the drug hav ...

Wall Street analysts expect Biogen Inc. (BIIB) to post quarterly earnings of $3.16 per share in its upcoming report, which indicates a year-over-year decline of 22%. Revenues are expected to be $2.46 billion, down 3.4% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 0.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timefram ...

Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 13, 2024, might help the stock move higher if these key numbers are better than ...

股价表现 - Biogen Inc. (BIIB) 最新收盘价为 $243.72，较前一日下跌了 1.66% [1] - Biogen Inc. (BIIB) 近一个月股价下跌了 4.78%，落后于医疗行业的涨幅 4.02% 和标普500指数的涨幅 2.93% [2] 财务预测 - Biogen Inc. (BIIB) 即将发布财报，预计每股收益为 $3.16，较去年同期下降了 21.98%，预计营收为 $2.46 亿美元，较去年同期下降了 3.43% [3] - 分析师对 Biogen Inc. (BIIB) 的最新预测调整可能反映了短期业务模式的变化，积极的预测调整可能预示着公司业务前景良好 [4] 股票评级 - Biogen Inc. (BIIB) 目前的 Zacks Rank 为 3 (Hold)，Zacks Consensus EPS 预测在过去30天内下降了 0.16% [6] 估值指标 - Biogen Inc. (BIIB) 目前的前瞻市盈率为 15.75，低于行业平均值 21.16，显示公司目前以折扣价交易 [7] - BIIB 目前的 PEG 比率为 2.7，结合了公司预期的盈利增长率 [8] 行业比较 - 医疗 - 生物医学和遗传学行业的平均 PEG 比率为 1.79 [9] - 医疗 - 生物医学和遗传学行业是医疗行业的一部分，目前该行业的 Zacks Industry Rank 为 96，在所有 250+ 个行业中排名前 39% [10] 行业排名 - Zacks Industry Rank 按照每个行业内公司的平均 Zacks Rank 从好到坏排序，研究显示排名前50%的行业的表现是排名后50%的两倍 [11]

Biogen公司调整药物开发策略 - Biogen宣布重新调整资源，加快新药Leqembi的开发，并停止争议性AD药物Aduhelm的开发和商业化[1][3] - Aduhelm虽然曾被视为潜在的爆款产品，但由于Medicare拒绝覆盖，导致需求降低至最低水平[5] - Biogen计划终止Aduhelm的后市场确认研究，并寻求合作伙伴来分享Aduhelm研究的整体成本[6] - Biogen未能找到Aduhelm研究所需的战略合作伙伴或外部融资，将把Aduhelm的权利归还给Neurimmune，并录得约6000万美元的一次性费用[7] 新药Leqembi的发展和市场前景 - Biogen计划推进新的AD药物Leqembi/lecanemab，该药已获得FDA批准，并在2023年7月获得CMS的广泛报销[9] - 欧洲药品管理局目前正在审查Leqembi的营销申请，Biogen的日本合作伙伴Eisai宣布将举行会议讨论Leqembi的营销授权申请[10] - Biogen与Eisai合作开发Leqembi，Eisai主导临床开发和监管提交，两家公司共同推广该药[11]

Biogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer's drug Aduhelm to refocus the company's efforts to treat the memory-robbing disease. The biotech company will focus on rolling out Leqembi, a newly approved Alzheimer's drug it developed with the Japanese drugmaker Eisai. It also plans to work on a slate of experimental treatments for the disease. Those drugs represent a new chapter for the company after the polarizing launch and approval of ...

Biogen公司决定停止Aduhelm开发 - Biogen公司宣布停止开发和商业化其阿尔茨海默病药物Aduhelm[1] - 公司表示，决定停止Aduhelm与安全或有效性问题无关，而是由于未能找到战略合作伙伴或外部融资[1] Biogen公司转向Leqembi药物 - 公司将继续推进获得美国食品和药物管理局去年全面批准的阿尔茨海默病治疗药物Leqembi[1] Aduhelm终止带来一次性费用 - 公司因Aduhelm的结算成本录得了约6000万美元的一次性第四季度费用[1] 资源重新部署在阿尔茨海默病业务中 - Biogen公司称，终止Aduhelm将释放出的许多资源将重新部署在公司的阿尔茨海默病业务中[1]

Company to reprioritize resources allocated to ADUHELM® (aducanumab-avwa) to advance LEQEMBI® (lecanemab-irmb) and to develop new treatment modalitiesBiogen committed to building a leading Alzheimer's disease franchise to address patient needs CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced plans to reprioritize its resources in Alzheimer's disease (AD), a strategic therapeutic area expected to drive near and long-term growth. The company will continue to advanc ...

In the latest market close, Biogen Inc. (BIIB) reached $247.52, with a +1.1% movement compared to the previous day. This change outpaced the S&P 500's 0.76% gain on the day. Elsewhere, the Dow gained 0.59%, while the tech-heavy Nasdaq added 1.12%.Shares of the company have depreciated by 5.39% over the course of the past month, underperforming the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5%.The upcoming earnings release of Biogen Inc. will be of great interest to investors. The company's e ...

盈利预期 - Biogen Inc.的盈利预期一直在上升，部分归功于盈利惊喜的历史。再加上股票的积极Zacks Earnings ESP (预期惊喜预测)，这是未来盈利惊喜的良好指标，尤其是与其稳定的Zacks Rank结合时[4] - 研究显示，具有积极的Earnings ESP和Zacks Rank 3 (Hold)或更好的股票，近70%的时间会产生积极的盈利惊喜。换句话说，如果有10支股票具备这种组合，超过预期的股票数量可能高达七支[5] - Zacks Earnings ESP比较了最准确的预期和本季度的Zacks Consensus Estimate；最准确的预期是Zacks Consensus的一个版本，其定义与变化相关。分析师在发布盈利报告前修订他们的预期，拥有最新信息，这可能比他们和其他人之前预测的更准确[6] - Biogen Inc.目前的Earnings ESP为+2.67%，这表明分析师最近对公司的盈利前景变得乐观。这一积极的Earnings ESP与股票的Zacks Rank 3 (Hold)结合，表明可能会有另一次盈利惊喜。我们预计公司的下一个盈利报告将于2024年2月13日发布[7] - 投资者应该注意，负的Earnings ESP并不意味着盈利不达预期，但负值会降低这一指标的预测能力[8] 盈利报告 - 过去两个季度的平均盈利惊喜达到了7.95%[2] - 最近一个季度，Biogen Inc.的盈利预期为每股3.99美元，实际报告为每股4.36美元，超出预期9.27%；前一个季度，预期为每股3.77美元，实际为每股4.02美元，超出预期6.63%[3] 投资建议 - 许多公司最终会超过共识的每股盈利预期，尽管这不是他们的股票上涨的唯一原因。此外，即使他们最终未达到共识预期，一些股票可能仍然保持稳定[9] - 因此，提前检查公司的Earnings ESP对于增加成功的几率非常重要。确保使用我们的Earnings ESP Filter，在他们发布盈利报告之前发现最佳的买入或卖出股票[10] 行业趋势 - Biogen Inc. (BIIB)属于Zacks Medical - Biomedical and Genetics行业，一直在稳定地击败盈利预期，可能在下一个季度报告中继续保持这一趋势[1]